CDC ENTEBBE

Erica Hayes, a long COVID patient, highlights the lack of FDA-approved treatments despite $1.15 billion in NIH funding. The NIH's RECOVER initiative, criticized for insufficient clinical trials, is now allocating $515 million more with a focus on trials. Patient advocates urge for trials on prescription-only interventions, not over-the-counter supplements or therapies. The NIH's RECOVER has funded over 200 observational studies and 40 pathobiology studies, but clinical trial results have been limited. The initiative aims to advance treatments for long COVID through rapid, collaborative, and transparent research.

Seoul National University scientists developed an AI-based diagnostic test for sepsis, reducing AST time by 30-40 hours, potentially preventing antimicrobial resistance and saving lives.

Lawmakers decided not to advance legislation that could expand veteran access to breakthrough therapies for mental health, including psilocybin. Bills proposed an advisory council to study and recommend how these therapies could help prevent veteran suicide. Psilocybin, classified as a Schedule I substance, has shown potential in treating PTSD and depression, according to Johns Hopkins Medicine. Veterans have testified to the benefits of psilocybin, and the VA announced funding for research on its use in treating PTSD and depression.

President-elect Trump nominates Dr. David Weldon for CDC, Dr. Martin Makary for FDA, and Dr. Janette Nesheiwat for surgeon general, under controversial HHS head Robert F. Kennedy Jr., raising concerns about the politicization of health agencies.

A poll shows 47% of respondents approve of Robert F. Kennedy Jr. as Trump's Health and Human Services secretary pick, despite Republican concerns about his stances on abortion and vaccines. Kennedy received the highest marks among Trump's nominees, with 44% approving of Marco Rubio for Secretary of State. 59% of U.S. adults approve of Trump's transition process, but 75% believe Senate should hold confirmation hearings.

Trump nominates Dr. Marty Makary to lead FDA, focusing on drug safety and reducing bureaucracy. He aligns with anti-vaccine advocate Robert F. Kennedy Jr., nominated for HHS. Trump also selects former Rep. Dave Weldon for CDC and Fox News contributor Janette Nesheiwat as surgeon general, reflecting a shift in public health policy.

In 2018, Samoan measles vaccine tragedy led to low immunization rates and a devastating outbreak. Robert F. Kennedy Jr. visited and criticized vaccination efforts. Trump nominated Kennedy to lead U.S. Health and Human Services, despite Kennedy's controversial views on vaccines, fluoride, and COVID remedies. Kennedy's concerns about chronic disease and corporate influence in healthcare could align with public health priorities, but his unscientific stance may hinder his confirmation.

President-elect Donald Trump nominates Johns Hopkins University surgeon Dr. Martin Makary as FDA commissioner. Makary, known for his healthcare reform books and media appearances, would report to Robert F. Kennedy Jr., HHS secretary with vaccine skepticism. AdvaMed supports Makary's nomination, emphasizing the importance of FDA's role in medical technology access.

Naltrexone effects on alcohol use, receptor interactions, and cellular responses are extensively studied, with references detailing its impact on self-administration, ethanol consumption, and opioid receptor dynamics in live cells.

President-elect Trump nominates Dr. Marty Makary to lead FDA, focusing on reducing bureaucracy and restoring scientific standards. Makary, a Johns Hopkins professor, opposes vaccine mandates and has criticized overprescribing and drug company influence. Trump also selects Dr. Dave Weldon for CDC and Janette Nesheiwat for Surgeon General, reflecting a shift in public health leadership.